Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Total Non-Current Liabilities (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Total Non-Current Liabilities for 9 consecutive years, with $18.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Non-Current Liabilities fell 10.33% to $18.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $18.7 million, a 10.33% decrease, with the full-year FY2024 number at $27.0 million, down 28.99% from a year prior.
  • Total Non-Current Liabilities was $18.7 million for Q3 2025 at Gyre Therapeutics, down from $21.8 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $38.0 million in Q4 2023 to a low of $1.8 million in Q1 2023.
  • A 4-year average of $20.3 million and a median of $20.9 million in 2024 define the central range for Total Non-Current Liabilities.
  • Biggest YoY gain for Total Non-Current Liabilities was 979.83% in 2024; the steepest drop was 28.99% in 2024.
  • Gyre Therapeutics' Total Non-Current Liabilities stood at $12.5 million in 2022, then skyrocketed by 204.59% to $38.0 million in 2023, then decreased by 28.99% to $27.0 million in 2024, then plummeted by 30.57% to $18.7 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Total Non-Current Liabilities are $18.7 million (Q3 2025), $21.8 million (Q2 2025), and $22.1 million (Q1 2025).